Denver, Colorado – TheNewswire - March 5, 2020 – CBD Global Sciences Inc. (CSE:CBDN) (CNSX:CBDN.CN) (OTC:CBDNF) (Frankfurt: GS3), (“CBD Global” or the “Company”), and our cannabidiol (“CBD”) brand “Aethics”, are excited to announce it has finalized the development and launch of a line of edible format gummies (the “Gummies” or “Gummy”) providing measurable consumption of convenient bite-sized CBD hemp extract that will be available in both full spectrum and broad spectrum formats. The Gummies will be offered in a variety of flavors and doses between 10-25 milligrams of CBD hemp extract per Gummy.  

The market for gummy wellness vitamins is forecasted to rise at a compound annual growth rate of ~6% between 2019-2029 reaching an aggregate value of US ~$5.8 billion in 2029 according to Transparency Market Research (https://www.transparencymarketresearch.com/gummy-vitamins-market.html).  CBD infused gummies are increasingly gaining popularity as more people realize the benefits of CBD.

CBD Global is launching their Gummy line under the Aethics brand and is also providing full service private label of our Gummies to our carefully selected partners.  We offer complete start-to-finish product development services with the current capacity to manufacture up to 4,000,000 units per week in the shapes and flavors preferred by our customers.

Brad Wyatt, CEO & President of the Company, states, “We are excited to offer a new line of high-quality products under our own Aethics brand and to our growing list of distribution partners”. Mr. Wyatt also added, “We will continue our efforts to add high quality products to our line-up and to demonstrate our commitment in listening to our customers and partners needs in the ever-changing CBD marketplace”.

ABOUT CBD GLOBAL SCIENCES INC.

CBD Global Sciences Inc., is a vertically integrated hemp-based CBD producer, extractor, and branding investment vehicle which currently owns two product categories, branded under the name AETHICS (www.aethics.com) and CANNAOIL (www.cannaoilshop.com), which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals and CBD hydration products.  CBD Global’s hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online.

CBD Global Sciences, through its wholly owned subsidiary, Strasburg Pharms, grows and operates irrigated land in Colorado that grows hemp with only all-natural Colorado water, soil, sun and nutrients that is NEVER sprayed with pesticides or chemicals.  Our genetics are hand selected and maintained to present the best cannabinoid profile with extremely high CBD.  The extraction/processing facility, operated by CBD Global, is located approximately 40 minutes from the farm.

For further information, please contact Bruce Nurse, Investor Relations, (303) 919-2913, info@cbdglobalsciences.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to future developments and the business and operations of the Corporation after the CSE listing.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and delay or failure to receive board, shareholder or regulatory approvals.  Readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES